Mayr-Melnhof Karton AG (MMK) Fair Value & Analysis
Consumer Cyclical · AT · Market cap €1.5B
Fair value as of: Jun 24, 2026
Analysis
Mayr-Melnhof Karton AG (MMK) currently trades at €77.50, while our model-based Fair Value estimate is €66.14 — implying the stock looks roughly 14.7% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Mayr-Melnhof Karton AG, together with its subsidiaries, manufactures and sells carton boards, paper, and folding cartons primarily in Europe. It operates through three segments: MM Food & Premium Packaging, MM Pharma & Healthcare Packaging, and MM Board & Paper. The MM Food & Premium segment processes carton boards into folding cartons primarily for the food industry and other consumer goods industries. The MM Pharma & Healthcare Packaging segment processes carton boards into folding cartons for the pharmaceutical industry, as well as leaflets and labels. The MM Board & Paper segment manufactures and markets carton boards focusing on coated carton board produced from recycled fibres, as well as virgin fibre-based carton boards. It also offers kraft papers, uncoated fine papers, and pulp. The company was founded in 1888 and is based in Vienna, Austria.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Mayr-Melnhof Karton AG (MMK) undervalued?
What is the fair value of MMK?
What is the quality score of MMK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.